Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) insider Bros. Advisors Lp Baker purchased 885,000 shares of the business’s stock in a transaction dated Thursday, October 5th. The shares were bought at an average price of $17.00 per share, with a total value of $15,045,000.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.
Shares of Rhythm Pharmaceuticals Inc (RYTM) opened at 25.25 on Monday. Rhythm Pharmaceuticals Inc has a 1-year low of $23.21 and a 1-year high of $33.81. The company’s market capitalization is $658.37 million.
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.
Receive News & Ratings for Rhythm Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.